LENZ Therapeutics LENZ
NASDAQ LENZ
$4.68 +0.02 (+0.43%)
At close: Aug 21, 2026 · 4:00 PM EDT

LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023)

LENZ Therapeutics (LENZ) posted quarterly Preferred Stock Liabilities of $143.4 million for Q4 2023, up 221.35% quarter-over-quarter from $44.6 million in Q3 2023.

LENZ Therapeutics (LENZ) Preferred Stock Liabilities (2020 - 2023) Analysis & Trends

LENZ Therapeutics (LENZ) has reported Preferred Stock Liabilities for 3 consecutive years, with $143.4 million the latest figure, recorded in Q4 2023.

  • In Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $143.4 million; the TTM figure through Dec 2023 stood at $143.4 million (changed N/A YoY), while the FY2023 annual figure was $143.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities advanced to $143.4 million in Q4 2023 per LENZ's latest filing, from $44.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $143.4 million in Q4 2023 and bottomed at $9.9 million in Q2 2023.
  • Historically, Preferred Stock Liabilities has averaged $53.9 million across 3 years, with a median of $44.6 million in 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 LENZ Therapeutics 147.30 Mn 147.30 Mn 5.21 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 143.39 Mn
Sep 30, 2023 44.62 Mn
Jun 30, 2023 9.89 Mn
Mar 31, 2023 44.62 Mn
Mar 31, 2021 110.01 Mn
Dec 31, 2020 55.61 Mn
Sep 30, 2020 11.51 Mn
Jun 30, 2020 11.51 Mn